Nykode Therapeutics AS (OTCMKTS:VACBF) Short Interest Update

Nykode Therapeutics AS (OTCMKTS:VACBF) was the target of a large drop in short interest in the month of April. As of April 15th, there was short interest totaling 41,779 shares, a drop of 87.3% from the March 31st total of 329,150 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days.

Nykode Therapeutics AS Stock Performance

Shares of VACBF stock opened at $0.38 on Friday. The firm has a fifty day simple moving average of $0.38 and a two-hundred day simple moving average of $0.27. Nykode Therapeutics AS has a 12 month low of $0.16 and a 12 month high of $0.38.

Nykode Therapeutics AS Company Profile

Nykode Therapeutics AS (OTCMKTS:VACBF) is a clinical-stage biotechnology company based in Oslo, Norway, focused on the development of precisely targeted immunotherapies. The company’s proprietary platform is designed to deliver antigenic payloads directly to antigen-presenting cells, with the goal of eliciting potent and durable immune responses against both cancerous and infectious disease targets. By combining modular antigen design with novel delivery modalities, Nykode aims to drive next-generation vaccine and immunotherapy solutions.

The company’s clinical pipeline includes several lead candidates in oncology and infectious diseases.